Is there an Indian generic version of Entrectinib?

Entrectinib is a targeted therapy drug that belongs to the category of receptor tyrosine kinase (RTK) inhibitors. Its main function is to inhibit the growth and spread of tumors by inhibiting NTRK (neuronal growth factor receptor kinase) gene fusion and ROS proto-oncogene 1, receptor tyrosine kinase (ROS proto-oncogene 1, receptor tyrosine kinase) gene fusion and ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) gene rearrangement tumors.

Entrectinib is now on the market in China and has been included in medical insurance. Patients can purchase it domestically. However, it is quite expensive, costing about 20,000 yuan. For detailed information on specific prices and medical insurance reimbursement, please consult your local hospital pharmacy.

There are currently no generic drugs officially marketed abroad. The ones marketed abroad are mainly Lao generic drugs, priced at only about one to two thousand yuan. It is worth mentioning that the ingredients of these generic drugs are basically the same as those of the original drugs.

The mechanism of action of entrectinib involves its binding to NTRK and ROS1 proteins, thereby blocking the abnormal activity of these proteins and slowing down the proliferation and metastasis of cancer cells. Mutations or rearrangements in the NTRK and ROS1 genes are relatively common in some tumors, and entrectinib targets these abnormally active proteins, making it an effective drug for treating these tumors.

This drug is mainly suitable for various tumor types carrying NTRK gene fusion or ROS1 gene rearrangement, including but not limited to non-small cell lung cancer, breast cancer, pancreatic cancer, soft tissue sarcoma, etc. Therefore, entrectinib is considered a cross-tumor therapeutic agent, providing an important treatment option for these patients.

Clinical trial results show that entrectinib is effective in NTRK gene fusion or ROS1It has shown good efficacy in patients with tumors that are positive for gene rearrangements. It significantly extends patient survival and is generally well tolerated. Entrectinib provides an important treatment option for patients for whom conventional treatments are ineffective or intolerable.